Pharmaceuticals, Biotechnology and Life Sciences
Alvogen announced today the completion of the sale of its Central and Eastern European (CEE) business to Zentiva for an undisclosed value. The sale of the company’s CEE platform includes over 200 generic and over-the-counter products across multiple therapeutic areas and covering 14 key markets.
Switzerland-based ObsEva SA has nominated Fabien de Ladonchamps, Vice President Corporate Affairs & Finance, as interim Chief Financial Officer and member of the Executive Committee.
Novartis said on Thursday it aims to start a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for the treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.
Sanofi and Regeneron’s phase 3 clinical trial results announced Friday show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) in children aged 6-11 years with uncontrolled severe atopic dermatitis significantly improved disease signs, symptoms and health-related quality of life.
Hygiena, a global leader in rapid microbial detection, monitoring, and identification technology, introduced the InSite L. mono Glo Environmental Surface Screening Test. InSite L. mono Glo Environmental Surface Screening Test. InSite L. monoGlo is an easy-to-use, self-contained, environmental sampling and screening test for Listeria species and Listeria monocytogenes (L. mono).
The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, reports that many of its member companies are actively involved in helping their clients develop and produce treatments, vaccines, and diagnostics for COVID-19. PBOA’s members provide a wide array of services throughout the bio/pharma sector.
PCR Biosystems, the UK-based PCR experts, PCR Biosystems has the capacity to manufacture enough reagent daily for 4 million reactions – which is sufficient for millions of diagnostic tests
Apeiron Biologics AG has received regulatory approvals in Austria, Germany and Denmark to kickoff a Phase II clinical trial of APN01 to treat COVID-19.
The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered…
Swiss-based Lonza has launched the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications.